You are here: Industry Insights > Novartis

News List

England's cost watchdogs nix Novartis' Kymriah for adults fiercepharma
September 30, 2018
Cost watchdogs in England turned away Kymriah in adults with relapsed or refractory diffuse large B-cell lymphoma after two prior therapies.
Mundipharma, Novartis to distribute pain medicine in SE Asia biospectrumasia
September 29, 2018
Novartis will retain all international development responsibility, as well as clinical development activities.
Novartis joins forces with GARDP for better, accessible infectious disease treatments in the developing world pharmafile
September 29, 2018
Novartis has partnered up with the Global Antibiotic Research & Development Partnership (GARDP) to push for faster development and wider availability for children...
Novartis collaborates with Cellular Biomedicine for CAR-T Therapy biospectrum
September 29, 2018
Novartis will be the exclusive holder of the marketing license.
Novartis strike $40m deal with Chinese firm Cellular Biomedicine pharmafile
September 29, 2018
Swiss multinational Novartis have paired up with Chinese drugmaker Cellular Biomedicine (CBMG) in order to manufacture CAR-T therapy Kymriah in the People’s Republic of China (PRC).
Novartis to cut 2,200 jobs in Switzerland to boost profits pharmaphorum
September 27, 2018
Novartis has announced that it will cut 2,200 jobs in Switzerland to boost its profitability.
High Court rejects Novartis, Bayer’s bid to outlaw off-label Avastin pharmatimes
September 27, 2018
Bayer and Novartis have lost a landmark case in the UK seeking to prevent the off-label use of Roche’s Avastin to treat wet AMD...
Novartis to file Lucentis for rare sight condition in premature babies pharmatimes
September 27, 2018
Novartis has revealed its intent to file anti-VEGF therapy Lucentis for retinopathy of prematurity (ROP), a rare disease...
Novartis to shutter Grimsby site amid manufacturing overhaul pharmatimes
September 27, 2018
Novartis has announced plans to close its manufacturing site in Grimsby, UK, by the end of 2020, among a wider job cull likely...
Novartis, axing 19% of its workforce, faces big challenges with thinned ranks fiercepharma
September 26, 2018
When Novartis created its business services unit in 2014, creating $3 billion in what the company called “productivity gains” as it reduced the costs associated with its back-office operations.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page